We found that treatment with an antibody that interferes with cell surface function of GRP78 inhibited both reprogramming efficiency, and pluripotent stem cell and breast cancer cell functions, supporting a cell surface signaling function of sGRP78 in mediating these effects. This evidence concerns the gene HSPA5 and breast cancer.